NASDAQ:ICPT - Intercept Pharmaceuticals Price Target & Analyst Ratings

Sign in or create an account to add this stock to your watchlist.
$111.35 +2.01 (+1.84 %)
(As of 03/26/2019 04:00 PM ET)
Previous Close$109.34
Today's Range$109.45 - $111.88
52-Week Range$58.03 - $133.74
Volume311,200 shs
Average Volume995,316 shs
Market Capitalization$3.31 billion
P/E Ratio-10.19
Dividend YieldN/A
Beta1.62

Analyst Ratings

Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Intercept Pharmaceuticals in the last 12 months. Their average twelve-month price target is $147.10, suggesting that the stock has a possible upside of 32.11%. The high price target for ICPT is $251.00 and the low price target for ICPT is $68.00. There are currently 2 sell ratings, 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.622.572.742.50
Ratings Breakdown: 2 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $147.10$145.40$150.6875$131.2222
Price Target Upside: 32.11% upside62.02% upside44.07% upside13.16% upside

Intercept Pharmaceuticals (NASDAQ:ICPT) Consensus Price Target History

Price Target History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2019OppenheimerReiterated RatingBuyLowView Rating Details
3/5/2019WedbushSet Price TargetBuy$251.00MediumView Rating Details
3/1/2019Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$130.00HighView Rating Details
2/28/2019B. RileyReiterated RatingBuy ➝ Buy$155.00 ➝ $169.00HighView Rating Details
2/28/2019Raymond JamesSet Price TargetStrong-Buy ➝ Buy$184.00 ➝ $187.00HighView Rating Details
2/28/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$170.00 ➝ $191.00HighView Rating Details
2/22/2019Svb LeerinkDowngradeMarket Perform ➝ Underperform$70.00MediumView Rating Details
2/22/2019Leerink SwannDowngradeOutperform ➝ Market Perform$70.00MediumView Rating Details
2/21/2019CitigroupBoost Price TargetNeutral ➝ Neutral$106.00 ➝ $140.00HighView Rating Details
2/20/2019JMP SecuritiesBoost Price TargetOutperform ➝ In-Line$175.00 ➝ $200.00HighView Rating Details
2/19/2019Wells Fargo & CoBoost Price TargetMarket Perform$75.00 ➝ $127.00HighView Rating Details
2/15/2019Bank of AmericaReiterated RatingUnderperform$68.00LowView Rating Details
2/12/2019Credit Suisse GroupReiterated RatingOutperformHighView Rating Details
1/28/2019Jefferies Financial GroupBoost Price TargetBuy$150.00LowView Rating Details
1/24/2019Needham & Company LLCUpgradeHold ➝ Buy$150.00HighView Rating Details
1/23/2019UBS GroupInitiated CoverageBuy ➝ Buy$130.00LowView Rating Details
1/14/2019LaidlawUpgradeHold ➝ Buy$99.00 ➝ $130.00LowView Rating Details
11/19/2018CIBCUpgradeMarket Perform ➝ OutperformMediumView Rating Details
9/12/2018Roth CapitalInitiated CoverageBuy ➝ Buy$192.00LowView Rating Details
8/6/2018Goldman Sachs GroupUpgradeSell ➝ Buy$46.00 ➝ $157.00HighView Rating Details
5/9/2018CowenReiterated RatingBuy$88.00LowView Rating Details
2/15/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$152.00 ➝ $155.00HighView Rating Details
2/12/2018Deutsche BankInitiated CoverageBuy$103.00MediumView Rating Details
1/25/2018Robert W. BairdReiterated RatingOutperform$332.00 ➝ $253.00LowView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$136.00N/AView Rating Details
9/22/2017Morgan StanleyReiterated RatingUnderweight$75.00 ➝ $50.00HighView Rating Details
(Data available from 3/26/2017 forward)
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel